Venous thromboembolic disease: Clinical practice guidelines in oncology Review uri icon

Overview

MeSH Major

  • Neoplasms
  • Venous Thromboembolism

abstract

  • Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying VTE in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that cancer patients in a high-risk setting for VTE (e.g., patients who have undergone cancer surgery, those with multiple myeloma) continue to receive VTE prophylaxis, with the duration of anticoagulation determined by the clinical situation. Careful evaluation of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE, is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered. © JNCCN-Journal of the National Comprehensive Cancer Network.

publication date

  • July 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3551573

PubMed ID

  • 21715723

Additional Document Info

start page

  • 714

end page

  • 77

volume

  • 9

number

  • 7